Viriom Incis A Commercial And Late Development Stage Biotech Company Developing Novel Therapies And Prevention Treatments Against Hiv And Hepatitis B Virushbv Viriom S Pipeline Includeselpidaa Elsulfavirine The Best In Class Nnrti That Received Its First Market Authorization In 2017Fixed Doze Combinations With Nucleoside Reverse Transcriptase Inhibitorsan Innovative Extended Release Weekly Oral Formulationand Vm1500A A Long Acting Injectable Therapy And Pre Exposure Prophylaxisviriom Is Also Developing A Highly Potent Prodrug Of The Antiviral Tenofoviractive Component Of Both Vemlidyaand Vireada To Treat Hiv And Hepatitis B Patientsviriom Believes Its Drug Candidates Are Capable Of Achieving Breakthroughs In Treatment And Prevention Of Hiv And Chronic Hbv Infections In Both Developing And Developed Countries
No conferences found for this company.
| Company Name | Viriom Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
